Myasthenia gravis complement activity is independent of autoantibody titer and disease severity

• Published in: PloS one 2022-01, Vol.17 (3)
• Main Authors: Miriam L. Fichtner, Michelle D. Hoarty, Douangsone D. Vadysirisack, Bailey Munro-Sheldon, Richard J. Nowak, Kevin C. O’Connor
• Format: Article
• Language: English
• ISSN: 1932-6203

Acetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Activation of the complement pathway in autoimmune diseases can lead to a secondary complement deficiency resulting in reduced complement activity, due to consumption, during episodes of disease activity. It is not clear whether complement activity in MG patients associates with measurements of disease activity or the titer of circulating pathogenic AChR autoantibodies. To explore such associations, as a means to identify a candidate biomarker, we measured complement activity in AChR MG samples (N = 51) using a CH50 hemolysis assay, then tested associations between these values and both clinical status and AChR autoantibody titer. The majority of the study subjects (88.2%) had complement activity within the range defined by healthy controls, while six patients (11.8%) showed reduced activity. No significant association between complement activity and disease status or AChR autoantibody titer was observed.